12 G5特異性結(jié)合表達(dá)重組CXCR 4的人和非人細(xì)胞。12 G5抑制一些HIV-2分離株的CD 4非依賴性感染,并且用12 G5預(yù)孵育細(xì)胞消除合胞體形成。HIV-2/vcp感染的細(xì)胞顯示12 G5結(jié)合的顯著和選擇性降低。12 G5還抑制HIV-1和HIV-2株誘導(dǎo)CXCR 4 + RD/CD 4細(xì)胞的細(xì)胞間融合。 原液抗人CXCR4(12G5)抗體該產(chǎn)品同種型對(duì)照:Mouse IgG2a In Vivo Isotype Control – Low Endotoxin (C1.18.4) [ICH2245] 緩沖液:ICH3001-100ml,nICH3002-100ml,nICH3003-100ml, 濃度:≥ 2.0 mg/ml 純度:>95% by SDS-PAGE 內(nèi)毒素:<1.0 EU/mg as determined by the LAL method 制劑:Sterile, preservative-free, solution in PBS. BSA and Azide free.
應(yīng)用類型
Blocking, Flow Cytometry, Immunocytochemistry, Immunofluorescence Microscopy, Immunohistochemistry, Neutralization, Western Blotting
免疫原
12G5 was produced by immunizing Balb/c mice with CP-MAC-infected Sup-T1 cells. Hybridomas were generated and screened for the ability to inhibit CP-MAC-induced syncytium induction on Sup-T1 cells.